gdc
FDA Approvals, News & UpdatesLiver CancerNewsworthy

Stivarga and Opdivo Newest Treatments for Liver Cancer

In 2017, the FDA approved two new treatments for patients with hepatocellular carcinoma (HCC), Stivarga and Opdivo. Read about these new treatments for liver cancer.
December 2017 Vol 3 No 6

On April 27, 2017, the FDA approved Stivarga (regorafenib, from Bayer HealthCare) for the treatment of patients with the most common type of liver cancer, called hepatocellular carcinoma (HCC), after they received sorafenib.

Stivarga, a kinase inhibitor that blocks the activity of several enzymes that promote cancer growth, is the first drug in almost a decade to be approved by the FDA for liver cancer. Stivarga was previously approved for the treatment of patients with colorectal cancer or gastrointestinal stromal tumors that stopped responding to other treatments.

On September 26, 2017, the FDA approved Opdivo (nivolumab, from Bristol-Myers Squibb), for patients with HCC, after being treated with sorafenib. Opdivo is the first immunotherapy approved by the FDA for patients with HCC and the second new treatment approved in the past decade for liver cancer.

The FDA approval of Opdivo for liver cancer was based on a study showing that 22 patients responded to treatment with Opdivo; of these patients, the cancer was in complete remission in 3 patients after treatment with Opdivo, and 19 patients saw their tumors shrink significantly. Opdivo was previously approved for many other types of cancer.

Recommended For You
Breast CancerFDA Approvals, News & UpdatesImmunotherapy
First Immunotherapy Approved for Patients with Advanced or Metastatic Triple-Negative Breast Cancer Expressing PD-L1
In March 2019, the FDA approved Tecentriq (atezolizumab), a PD-L1 inhibitor, in combination with Abraxane (paclitaxel protein-bound), for use in adults with locally advanced or metastatic triple-negative breast cancer whose tumors cannot be removed by surgery and express PD-L1, as identified by an FDA-approved test. This is the first FDA-approved immunotherapy for patients with advanced or metastatic triple-negative breast cancer.
FDA Approvals, News & UpdatesGastric Cancer
Lonsurf Approved for Metastatic Gastric or Gastroesophageal Junction Cancer
In February 2019, the FDA approved Lonsurf for the treatment of patients with metastatic gastric (stomach) cancer or gastroesophageal junction adenocarcinoma. This drug was previously approved only for patients with metastatic colorectal cancer.
Last modified: January 23, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country